Aqupla (nedaplatin) / Simcere - LARVOL DELTA

Otoprotective measures for cisplatin-based chemoradiotherapy-induced toxicity in patients with head and neck cancer: a systematic review and meta-analysis. (PubMed, Support Care Cancer) - "Through our systematic review, we identified a limited number of studies of measures to prevent the ototoxic effects of high-dose cisplatin-based CRT. Most studies had negative results, small patient populations, and were of low quality. Only low-dose cisplatin-based CRT tended to reduce the incidence of ototoxicity while maintaining survival data similar to those of high-dose cisplatin-based CRT."

Journal • Retrospective data • Review • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Exploratory clinical study of Iparomlimab and Tuvonralimab (QL1706) in combination with albumin paclitaxel and nedaplatin for locally advanced resectable squamous cell carcinoma of the esophagus (ESCC) (ChiCTR) - P=N/A | N=30 | Not yet recruiting | Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital

New trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Chromosome 11q13 amplification as a decision-making biomarker for anti-PD-1 immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma: a prospective cohort study. (PubMed, Front Immunol) - P=N/A | "Based on 11q13 amplification status, non-amplified patients received PD-1 inhibitor monotherapy or combination therapy with chemotherapy, while amplified patients were treated with cetuximab and chemotherapy. Nedaplatin was used in place of cisplatin if necessary...Patients without 11q13 amplification exhibited better responses to anti-PD-1 therapy, providing insights into optimizing treatment strategies. Chinese Clinical Trial Registry identifier, ChiCTR2000035635."

Biomarker • IO biomarker • Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial. (PubMed, Int J Cancer) - "The concurrent chemotherapy regimen comprised weekly doses of paclitaxel and nedaplatin for 5 weeks. SIB-RT should be realized as the essential treatment modality for inoperable ESCC. SIB-RT + CT should be the preferred treatment option, as it affords a superior treatment response and greater dysphagia relief."

Journal • P3 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Hematological Disorders • Leukopenia • Oncology • Squamous Cell Carcinoma

Efficacy and safety of immunotherapy combined with chemotherapy as conversion therapy for initially unresectable locally advanced esophageal squamous cell carcinoma (PubMed, Zhonghua Wai Ke Za Zhi) - "All patients received PD-1 inhibitor sintilimab combined with nedaplatin and albumin-bound paclitaxel. Among the 32 patients, the ORR was 56.3% (95%CI:37.7% to 73.6%),the 3-year EFS rate and OS rate was 59.4%(95%CI:40.8% to 86.4%) and 59.7%(95%CI:40.0% to 89.0%) respectively. Immunotherapy combined with chemotherapy demonstrates high conversion rates and favorable safety in the conversion therapy of initially unresectable locally advanced esophageal squamous cell carcinoma, representing a promising treatment strategy."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Effect of Prophylactic Thrombopoietin and Magnetic Resonance Guided Bone Marrow-Sparing Concurrent Chemoradiotherapy on Thrombocytopenia for Thoracic Esophageal Cancer: Final Analysis of a Phase II Study (ASTRO 2025) - P2 | "The treatment regimen consisted of BM-sparing intensity modulated radiotherapy (BMS-IMRT) (=45Gy) and concurrent chemotherapy (five cycles of weekly intravenous paclitaxel [50 mg/m²] and cisplatin/nedaplatin [25 mg/m²], or two cycles of intravenous paclitaxel [135-175 mg/m²] and cisplatin [80 mg/m²]), and rhTPO (15000U ih. Techniques to limit low dose radiation to active BM and prophylactic rhTPO could reduce thrombocytopenia in thoracic esophageal cancer patients treated with CRT. (registered in Clinical Trials.gov as NCT05944809)"

P2 data • Esophageal Cancer • Oncology

Intratumoral and peritumoral heterogeneity based on CT to predict the pathological response after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma. (PubMed, Int J Surg) - "The combined model integrating intratumoral and peritumoral habitat radiomics features with clinical variables can accurately predict MPR in ESCC patients after NACI and shows promising potential in predicting pCR."

Heterogeneity • Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Tislelizumab Combined With Low-Dose Chemotherapy in Previously Treated Advanced Squamous NSCLC (IASLC-WCLC 2025) - "Methods : All eligible patients received low-dose chemotherapy, either nedaplatin (NDP) at 50 mg/m2 or gemcitabine (GEM, for patients who had prior NDP exposure) at 1000 mg/m2 on day1, combined with tislelizumab at 200 mg on day 2. The primary endpoint was the 6-month progression-free survival (PFS) rate. Secondary endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), 1-year OS rate, and safety."

IO biomarker • Metastases • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Solid Tumor

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=86 | Recruiting | Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

PPIO-004-EC001: PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer (clinicaltrials.gov) - P2 | N=118 | Completed | Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Enrolling by invitation ➔ Completed | N=62 ➔ 118 | Trial completion date: Dec 2024 ➔ Aug 2025 | Trial primary completion date: Apr 2024 ➔ Aug 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Dual EGFR L858R and KRAS G12A Mutations in Lung Adenocarcinoma: A Rare Case Report and Literature Review. (PubMed, Pharmgenomics Pers Med) - "The patient started first-line therapy with osimertinib combined with pemetrexed/nedaplatin, resulting in a transient partial response, significant resolution of pleural effusion, and partial regression of the primary tumor. The patient achieved only transient disease control following treatment with a third-generation EGFR TKI combined with chemoradiotherapy. Further research to explore optimal therapeutic strategies for such complex molecular profiles is needed."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • EGFR • KRAS

A single-center, single-arm exploratory study based on AI imaging to evaluate the efficacy of toripalimab combined with albumin-paclitaxel and nedaplatin neoadjuvant therapy for esophageal cancer (ChiCTR) - P4 | N=50 | Not yet recruiting | Sponsor: Gansu Provincial Hospital; Gansu Provincial People's Hospital

New P4 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology

Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer. (PubMed, Sci Rep) - "Patients were divided into two groups: an experimental group (n = 41) treated with a combination of platinum-based chemotherapy (pemetrexed and nedaplatin) and the PD-1 inhibitor cindilizumab, and a control group (n = 41) treated with conventional platinum-based chemotherapy. These findings support the integration of neoadjuvant immunotherapy and chemotherapy as a promising strategy for treating stage IIIa NSCLC, offering improved resection rates, survival, and reduced complications. Further research is warranted to optimize treatment protocols and validate these results in larger, multicentre studies."

IO biomarker • Journal • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CK19 • KRT19

Prolonged Progression-Free Survival in a Patient with Highly Pretreated Recurrent Ovarian Cancer after Developing Multisystem Immune-Related Adverse Events: A Case Report and Literature Review. (PubMed, Case Rep Oncol) - "Between 2013 and 2021, she underwent palliative chemotherapy comprising paclitaxel liposomes, cisplatin/nedaplatin, S-1/raltitrexed, irinotecan, doxorubicin, vinorebine, toripalimab, apatinib, gemcitabine, oxaliplatin, and capecitabine, as well as two debulking surgeries. From November 2021, she received six cycles of tislelizumab (a PD-1 inhibitor), paclitaxel (albumin-bound), and carboplatin, to which a partial response was observed according to the Response Evaluation Criteria in Solid Tumors. From May 2022, the patient was switched to maintenance therapy with tislelizumab plus olaparib...We report a case involving a patient with highly pretreated recurrent ovarian cancer who exhibited prolonged PFS after developing three irAEs. The distinctly prolonged PFS observed, along with the reviewed literature, suggests that irAEs may be correlated with improved survival in ovarian cancer."

Adverse events • IO biomarker • Journal • Tumor mutational burden • Endocrine Disorders • Gynecology • Microsatellite Instability • Nephrology • Obstetrics • Oncology • Ovarian Cancer • Pneumonia • Renal Disease • Solid Tumor • MSI • TMB

Choroidal metastasis as the first sign of small cell lung cancer: A case report. (PubMed, Oncol Lett) - "First-line chemotherapy regimens consisted of etoposide and nedaplatin, while second-line regimens consisted of liposomal paclitaxel combined with lobaplatin. Furthermore, palliative care, psychological support and socioeconomic assistance are key to the quality of life of patients. Adoption of a patient-centered approach to provide comfort can also optimize treatment outcomes and improve the quality of life of patients."

Journal • Lung Cancer • Oncology • Palliative care • Respiratory Diseases • Retinal Disorders • Small Cell Lung Cancer • Solid Tumor

Copper oxide nanoparticles as delivery vehicles for different Pt(II)-drugs: experimental and theoretical evaluation. (PubMed, J Mater Chem B) - "In this work, we examined the loading efficiency of cisplatin, oxaliplatin and nedaplatin on the surface of CuO nanoparticles by using experimental techniques such as UV-visible spectroscopy, FTIR spectroscopy, the BET method, and XRD, and theoretical ones based on DFT calculations under periodic boundary conditions (PBC). However, cisplatin has the most intense contact with the copper oxide surface, with an adsorption energy (Eads) of -3.0 eV. Both experimental and theoretical results highlight that CuO nanoparticles are excellent Pt(II) anticancer drug carriers, especially in the case of cisplatin, which undergoes strong interactions with the support, necessary for the delivery phase, and easy desorption, important in the antitumor action phase of the drug."

Journal • Oncology

Interactions of Nedaplatin with Nucleobases and Purine Alkaloids: Their Role in Cancer Therapy. (PubMed, Biomedicines) - "Background: Nedaplatin is a platinum-based anticancer drug that combines the benefits of Cisplatin and Carboplatin, retaining Cisplatin's anticancer activity while reducing toxicity similar to Carboplatin. These studies provide new insights into the molecular mechanisms of Nedaplatin's action and may contribute to a better understanding of its pharmacological interactions. However, research requires confirmation not only in in vivo studies but also in clinical trials."

Journal • Oncology

The usefulness of immunonutrition in chemotherapy and chemoradiotherapy for esophageal cancer. (PubMed, Oncol Lett) - "In the retrospective study, 32 patients were analyzed: 15 in the docetaxel, nedaplatin and 5-fluorouracil (DNF) group (OIN, 6; control, 9) and 17 in the docetaxel, cisplatin and 5-fluorouracil (DCF) with radiotherapy (DCF-RT) group (OIN, 7; control, 10). Although based on a limited number of patients, these results provide pilot evidence supporting the immunonutritional potential of OIN in esophageal cancer treatment. The prospective study (UMIN000056761) was retrospectively registered on January 21, 2025."

Journal • Esophageal Cancer • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Neutropenia • Oncology

Immune checkpoint inhibitors combined with targeted therapy for long-term survival in advanced pulmonary squamous cell carcinoma after first-line failure: A case report and literature review. (PubMed, Medicine (Baltimore)) - "This case underscores the potential efficacy of combining immune checkpoint inhibitors with small-molecule multi-targeted tyrosine kinase inhibitors in treating advanced SCC of the lung after progression on first-line therapy. The complementary mechanisms of immune modulation and tumor microenvironment normalization may offer an effective strategy for addressing immune resistance in SCC."

Checkpoint inhibition • IO biomarker • Journal • Cardiovascular • Cough • Endocrine Disorders • Hypertension • Immune Modulation • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • PD-L1

Long-term immune checkpoint inhibitor therapy in a patient with metastatic nasopharyngeal carcinoma: a case report. (PubMed, Front Immunol) - "Current pivotal trials predominantly advocate for a fixed two-year regimen of immune checkpoint inhibitors (ICIs), exemplified by pembrolizumab and toripalimab, as first-line therapy for patients with advanced malignancies. Alternatively, for specific ICIs, including nivolumab, camrelizumab, and tislelizumab, continuous administration until disease progression has emerged as a favored approach...The patient completed two cycles of induction chemotherapy with liposomal paclitaxel and nedaplatin, followed by platinum-based concurrent chemoradiotherapy, resulting in a progression-free survival (PFS) of 23.6 months...EBV DNA levels could serve as an informative marker to predict the necessity of therapy discontinuation during immunotherapy maintenance. Notably, a post-discontinuation ICI rechallenge can still yield favorable outcomes potentially accredited to immune memory."

Checkpoint inhibition • IO biomarker • Journal • Epstein-Barr Virus Infections • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Pain • Solid Tumor

Real-world data of docetaxel-induced liver injury among hospitalized patients in Wuhan, China: A retrospective analysis. (PubMed, Medicine (Baltimore)) - "Among these therapeutic combination regimens, docetaxel plus epirubicin, docetaxel plus nedaplatin, and docetaxel plus capecitabine could significantly increase the occurrence of docetaxel-induced liver injury during hospitalization respectively, while docetaxel plus cyclophosphamide regime might be safer. Therefore, for patients with these risk factors, it might be advisable to actively consider optimum management to reduce the occurrence of docetaxel-induced liver injury during hospitalization, particularly hepatic function test."

Journal • Observational data • Real-world evidence • Retrospective data • Diabetes • Hepatitis B • Hepatology • Infectious Disease • Liver Failure • Metabolic Disorders • Oncology • Ovarian Cancer • Solid Tumor

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma (clinicaltrials.gov) - P2 | N=26 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xiamen University

New P2 trial • Esophageal Cancer • Oncology • Squamous Cell Carcinoma

Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study. (ASCO 2025) - P1/2 | "The combination of fruquintinib, camrelizumab, paclitaxel liposome, and nedaplatin demonstrated significant efficacy and manageable toxicity profile as a first-line treatment for advanced ESCC, suggesting a potential new treatment strategy."

Clinical • Combination therapy • Metastases • P2 data • Anemia • Cardiovascular • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Hypertension • Leukopenia • Mucositis • Neutropenia • Oncology • Pain • Squamous Cell Carcinoma • Stomatitis

A phase II study of prophylactic thrombopoietin combined with magnetic resonance guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy and concurrent chemotherapy for thoracic esophageal cancer. (ASCO 2025) - P2 | "The treatment regimen consisted of BM-sparing intensity modulated radiotherapy (BMS-IMRT) (≥45Gy) and concurrent chemotherapy (five cycles of weekly intravenous paclitaxel [50 mg/m²] and cisplatin/nedaplatin [25 mg/m²], or two cycles of intravenous paclitaxel [135-175 mg/m²] and cisplatin [80 mg/m²]), and rhTPO (15000U ih. Techniques to limit low dose radiation to active BM and prophylactic rhTPO could reduce thrombocytopenia in thoracic EC patients treated with CRT."

P2 data • Anemia • Esophageal Cancer • Leukopenia • Oncology • Thrombocytopenia

Camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm exploratory study. (ASCO 2025) - P2 | "The combination of camrelizumab, paclitaxel, and nedaplatin demonstrates promising efficacy and manageable adverse effects as a conversion therapy, enhancing surgical resectability and survival outcomes without delaying surgery. Table 1. Survival outcomes."

Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma